Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028

加齢黄斑変性症(AMD)・その他網膜疾患治療薬の世界市場

◆タイトル:Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028
◆商品コード:VGN808051
◆調査・発行会社:visiongain
◆発行日:2018年5月
◆ページ数:171
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥388,656見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥431,856見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥719,856見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、加齢黄斑変性症(AMD)・その他網膜疾患治療薬の世界市場について調査・分析し、加齢黄斑変性症(AMD)・その他網膜疾患治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne – our new study reveals trends, R&D progress, and predicted revenues. Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2028, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 171-page report provides 140 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2018-2028 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2028 for the following submarkets:
• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast)

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?
How will individual retinal medicines perform from 2018 to 2028 at world level? Our study forecasts revenues of four prominent brands:
• Lucentis
• Eylea
• Avastin
• Visudyne

Discover how high revenues can go. See what’s happening, understanding the trends, challenges and opportunities.

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 11 leading national markets from 2018-2028:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth
Our analysis forecasts that the world market for retinal drugs will reach $14.85bn in 2018. It will achieve strong revenue expansion from 2018 to 2028. Our report reveals how high sales will go over the next 10 years.

Research and development – assess innovation, trends and possibilities
There you can also investigate R&D, appraising technological, clinical and commercial possibilities.
In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:
• Combination therapies, including neovascularisation disrupters
• Angiogenesis inhibition by blocking pericyte recruitment
• Anti-inflammatory mechanisms (inc. corticosteroids)
• Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
• Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:
• Oligonucleotides and siRNA therapy
• Anti-integrin oligopeptide treatment
• Complement factor inhibition and serotonin modifiers
• Angiotensin receptor blockers and converting enzyme inhibitors
• Biosimilars and other follow-on biologicals and next generation therapeutics
• Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne. Avoid missing out – get our report now.

【レポートの目次】

1. Report Overview

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analysis

1.5 Who Is This Study For?

1.6 Methods of Research and Analysis

1.7 Frequently Asked Questions (FAQs)

1.8 Some Associated Reports

1.9 About Visiongain

2. World AMD and Other Disease Market, 2017

2.1 What are Retinal Diseases?

2.2 Types of Retinal Diseases

2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases

2.4 Nearly 200 Million People with AMD?

2.5 Over 100 Million with DR

2.6 First RVO Estimates Suggest Patient Population of 16 Million

2.7 Market to Make Rapid Pace to 2028

2.8 Eylea Became Leading drug in the Market

2.9 Regeneron the Leading Presence in the Market

2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2017

3.1 Wet AMD Still the Main Source of Revenue in the Market

3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets

3.2.1 Revenue Forecasting for Wet AMD segment, 2017-2028

3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE

3.3.1 Dry AMD Segment to Emerge in the Forecast Period

3.4 DR: Coming Into Clinical Focus, with DME the Main Target

3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues

3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas

3.6 Projections for All Segmzents, 2017-2028

4. Approved Products in the AMD and Other Retinal Diseases Market, 2017-2028

4.1 Will the Current Products Dominate the Market Through 2028?

4.2 Lucentis: Second Leading Drug in the Market

4.2.1 Positive Revenue Growth Shown in Past: 2014-2017

4.2.2 Shadow of Avastin Still Hangs Over Lucentis

4.2.3 Lucentis/Avastin Matters

4.2.4 Eylea: The Bigger Threat to Lucentis?

4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond

4.2.6 Improving Cost and Compliance for Lucentis

4.2.7 Lucentis Revenue Forecast 2017-2028

4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?

4.3 Eylea: Holds the Throne?

4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified

4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?

4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?

4.3.4 Eylea into DME and Other New Indications

4.3.5 Eylea Revenue Forecast 2017-2028

4.3.6 How Far Can Eylea’s Momentum Carry It?

4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product 4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD

4.4.2 Judicial Review Averted in the UK by Price Adjustment

4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007

4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions

4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?

4.4.6 Avastin Revenue Forecast, 2017-2028

4.4.7 Will Anything Dislodge Avastin from its Central Position?

4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period

4.5.1 Visudyne Revenue Forecast, 2017-2028

4.6 Other Drugs for Macular Degeneration and Other Retinal Diseases

4.6.1 Other Drugs Revenue Forecast, 2017-2028

5. Pipeline for Wet AMD Segment, 2017-2028

5.1 The Leading Pipeline Candidates

5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?

5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results

5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort

5.2.3 Ophthotech Partners with Novartis for Fovista

5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment

5.2.5 The Move toward Combination Therapies

5.3 Other Growth Factor Targets in the Pipeline

5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop

5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF

5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options

5.4 APL-2: Evaluation for the treatment of patients with geographic atrophy (GA) related to AMD

5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?

5.4.2 Binding Affinity Comparable to Eylea

5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?

5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life

5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment

5.5.3 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent

5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development

5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way

5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches

5.6.1 Verisome System and IBI-30089 (Icon Bioscience)

5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?

5.7 Other Targets Under Investigation in wAMD Drug Development

5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?

5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running

5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor

5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)

5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?

5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide

5.7.7 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003

5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation

5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD

5.8 Regenerative Medicine Approaches

5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis

5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD

5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment, 2017-2028

6.1 Who Will Achieve the Big Breakthrough in Dry AMD?

6.2 MC-1101 (MacuCLEAR): Leading the Pack?

6.2.1 Increasing Choroidal Blood Flow with Repurposed Product

6.2.2 Novel Endpoints in Phase 3 Study

6.2.3 Can MacuCLEAR Make It?

6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3

6.3.1 Study Result Declared in May 2016

6.3.2 Other Visual Cycle Modulators

6.4 High Hopes for Complement Inhibition in Dry AMD

6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013

6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab

6.5 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis

6.5.1 Iluvien (Alimera Sciences): Study terminated

6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD

6.6 Neuroprotection: One of Modern Medicine’s Holy Grails

6.6.1 Tandospirone (Alcon): Not effective in GA

6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies

6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action

6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch

6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets

6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial

6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space

6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair

6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests

6.7.5 First iPSC Trial in Japan in Dry AMD Patients

6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD

6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2017-2028

7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population

7.2 Lucentis: The Game Changer for DR?

7.3 New Anti-VEGF Additions

7.3.1 Is Eylea Better than Lucentis and Avastin for DME?

7.4 Steroids in Development for DR

7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets

7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)

7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate

7.4.4 Cortiject (Santen): Prodrug Candidate

7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide

7.5 Other Products in Development for DR

7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation

7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?

7.5.3 TriLipix (Abbott): No New Development for Promising Drug

7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013

8. Regional Market Breakdown, 2017-2028

8.1 Which Markets Hold the Most Revenue Growth Potential?

8.2 The US: Leading Market for Retinal Diseases

8.3 Japan: Strong Market Potential

8.4 EU5: Ageing Populations to Drive Market Growth

8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Leading Companies in Global AMD and Other Retinal Diseases Market, 2017

9.1 Novartis AG

9.1.1 Company Overview

9.1.2 Financials

9.1.3 Key News

9.2 F. Hoffmann-La Roche Ltd

9.2.1 Company Overview

9.2.2 Financials

9.2.3 Key News

9.3 Bayer AG

9.3.1 Company Overview

9.3.2 Financials

9.3.3 Key News

9.4 Regeneron Pharmaceuticals

9.4.1 Company Overview

9.4.2 Financials

9.4.3 Key News


10. Qualitative Industry and Market Analysis, 2017-2028

10.1 Strengths: The Most Dynamic Area of the Ophthalmics Market

10.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach

10.3 Opportunities: New Markets and R&D Synergies

10.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?

10.5 Social: Low Diagnosis, Low Compliance

10.6 Technological: Innovation for the Eye

10.7 Economic: Off-Label Treatment and Reimbursement Issues

10.8 Political: The Demography and Diabetes Challenges


11. Research Interviews

11.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.

11.1.1 Major Changes in AMD and Other Retinal Diseases Market

11.1.2 The Landscape of Emerging Markets

11.1.3 Opportunities and Plans of Marken’s Network

11.1.4 DR Market Opportunities

11.2 Interview with Philip G. Ralston, Jr., MacuCLEAR

11.2.1 MC-1101: Progress in Clinical Trials

11.2.2 MC-1101 More Effective in Early to Mid-Range AMD

11.2.3 Partnerships and Expected Launch of MC-1101


12. Conclusions

12.1 The Age of Lucentis: Nearing Its Conclusion?

12.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market

12.3 Indications Outside Wet AMD to Gain in Importance

12.4 Dry AMD Market Has Huge Potential

12.5 Fovista Most Prominent Among the Pipeline Candidates

12.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics


Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Report Evaluation Form


Table of Tables

Table 1.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 1.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 2.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2017

Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2017

Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2017

Table 3.3 Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2022

Table 3.4 Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2028

Table 3.5 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2022

Table 3.6 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2028

Table 3.7 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2022

Table 3.8 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2028

Table 3.9 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 3.10 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 3.11 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2017, 2022 and 2028

Table 4.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2022

Table 4.4 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2028

Table 4.5 Lucentis: Revenue ($bn), AGR (%), 2014 & 2017

Table 4.6 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics

Table 4.7 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.8 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 4.9 Eylea: U.S. Revenue ($bn), AGR (%), 2016-2017

Table 4.10 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.11 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 4.12 Avastin: Revenue ($bn), AGR (%), 2015-2017

Table 4.13 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.14 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 4.15 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.16 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 4.17 Other Drugs Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.18 Other Drugs Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 5.1 Selected R&D Pipeline for wAMD, 2017

Table 6.1 Selected R&D Pipeline for Dry AMD, 2017

Table 7.1 Selected R&D Pipeline for DR, 2017

Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 8.2 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2012-2028

Table 8.3 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 8.4 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 8.5 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 8.6 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 8.7 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 8.8 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 8.9 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022

Table 8.10 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028

Table 9.1 Novartis AG: Overview 2017

Table 9.2 Novartis Revenue ($bn) 2016, 2017

Table 9.3 Roche: Overview 2017

Table 9.4 Roche Revenue ($bn) 2016, 2017

Table 9.5 Bayer: Overview 2017

Table 9.6 Novartis Revenue ($bn) 2016, 2017

Table 9.7 Regeneron Pharmaceuticals: Overview 2017

Table 9.8 Regeneron Pharmaceuticals: Revenue ($bn) 2016, 2017

Table 10.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2018

Table 10.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2018

Table 10.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2017-2028


Table of Figures

Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2017-2028

Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2017

Figure 2.3 Market Breakdown by Company: Market Share (%), 2017

Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2017

Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2017

Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2017

Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2022

Figure 3.3 Wet AMD Segment Forecast: Revenue ($bn), 2017-2028

Figure 3.4 Dry AMD Segment Forecast: Revenue ($bn), 2017-2028

Figure 3.5 DR Segment Forecast: Revenue ($bn), 2017-2028

Figure 3.6 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2017-2028

Figure 3.7 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2017, 2022 and 2028

Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2022

Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2028

Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2022

Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2028

Figure 4.3 Market Forecast by Product: Revenue ($bn), 2017-2028

Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2017, 2022 and 2028

Figure 4.5 Lucentis: Revenues Forecast ($bn), 2017-2028

Figure 4.6 Eylea Forecast: Revenue ($bn), 2017-2028

Figure 4.7 Drivers and Restraints for Eylea, 2017

Figure 4.8 Avastin Forecast: Revenue ($bn), 2017-2028

Figure 4.9 Drivers and Restraints for Avastin, 2017

Figure 4.10 Visudyne Forecast: Revenues ($bn), 2017-2028

Figure 4.11 Other Drugs Forecast: Revenues ($bn), 2017-2028

Figure 8.1 Regional Breakdown: Revenue ($bn), 2017-2028

Figure 8.2 Regional Breakdown: Revenue ($bn), 2017, 2022 and 2028

Figure 8.3 Regional Market Share (%), 2017

Figure 8.4 Regional Market Share (%), 2022

Figure 8.5 Regional Market Share (%), 2028

Figure 8.6 US Market: Revenue ($bn), 2017-2028

Figure 8.7 Japan: Revenue ($bn), 2017-2028

Figure 8.8 EU5: Grouped Revenue ($bn), 2017-2028

Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2017-2028

Figure 8.10 EU5 Breakdown: Market Share (%), 2017

Figure 8.11 EU5 Breakdown: Market Share (%), 2022

Figure 8.12 EU5 Breakdown: Market Share (%), 2028

Figure 8.13 BRIC Nations Forecast: Revenue ($bn), 2017-2028

Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2017-2028

Figure 8.15 Market Share (%) within BRIC Group by Country, 2017

Figure 8.16 Market Share (%) within BRIC Group by Country, 2022

Figure 8.17 Market Share (%) within BRIC Group by Country, 2028

★調査レポート[加齢黄斑変性症(AMD)・その他網膜疾患治療薬の世界市場] ( Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028 / VGN808051) 販売に関する免責事項
[加齢黄斑変性症(AMD)・その他網膜疾患治療薬の世界市場] ( Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028 / VGN808051) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆